FTC Targets Hemp Health Claims: What the New Warning Letter Wave Means for Your Marketing

The Federal Trade Commission has issued a new round of warning letters to hemp and CBD companies making what the agency characterizes as unsubstantiated health claims. The latest letters are notable not just for the specific claims targeted, but for the broader posture they signal: FTC is treating hemp marketing with the same substantiation standard it applies to dietary supplements and OTC drugs, and the agency is coordinating with FDA in a way that creates compounding risk for brands with aggressive health claim marketing.

For B2B hemp ingredient suppliers and the brands they supply, the FTC warning letter wave has direct implications for how hemp products are marketed — and for how ingredient suppliers document their product's attributes in ways that downstream customers can use without creating their own liability.

What the Warning Letters Target

FTC's latest warning letters target several categories of health claims that have been common in hemp marketing:

Disease treatment claims. Claims that hemp or CBD products treat, cure, or mitigate specific medical conditions — anxiety disorders, chronic pain, epilepsy, cancer — remain FTC's primary enforcement target. These claims require clinical substantiation at a standard the vast majority of hemp brands cannot meet, and FTC has been clear that "promotes relaxation" is acceptable while "treats anxiety disorder" is not.

Structure/function claims without adequate substantiation. Claims that a hemp product "supports cognitive function," "promotes healthy sleep," or "reduces inflammation" are structure/function claims that require competent and reliable scientific evidence under FTC's substantiation standard. The letters indicate that FTC is scrutinizing whether brands have the scientific evidence to back these claims or are relying on general awareness of cannabis research without product-specific substantiation.

Consumer testimonials presented as clinical evidence. FTC has been particularly critical of brands using customer reviews and testimonials that describe dramatic health outcomes in ways that imply the product treated a medical condition. Consumer testimonials are not a substitute for clinical substantiation, and brands presenting them as evidence of efficacy are creating deceptive advertising liability.

"Natural" and "plant-based" claims combined with efficacy claims. FTC is scrutinizing the combination of naturalness claims with implicit efficacy claims — framing that suggests a product's plant origin makes it both safe and effective for health purposes without separately substantiating the efficacy component.

The FDA Coordination Dynamic

FTC's warning letters are increasingly coordinated with FDA, which has parallel authority over health claims for food, dietary supplement, and drug products. The joint FTC-FDA enforcement posture creates compounding risk: a brand that receives an FTC warning for unsubstantiated health claims may also be flagged for FDA review of the same claims under the drug exclusion framework.

This coordination is not new — FTC and FDA have jointly issued hemp warning letters before — but the intensity of the coordination in 2026 reflects the agencies' shared interest in establishing clear enforcement standards before November 12 creates a more explicitly regulated hemp market.

What Claims Are Actually Permitted

Under FTC's substantiation standard and FDA's framework for hemp products, permitted claims fall into a few categories:

Truthful statements about the product's composition. Stating that a product contains a specific concentration of CBD, is made from USDA-licensed hemp, and is tested by accredited laboratories is factual product description, not a health claim, and carries no FTC enforcement risk.

General wellness language with appropriate context. Language like "part of a wellness routine" or "formulated for daily use" — without attaching specific health outcomes — falls within acceptable marketing territory. The line is crossed when wellness language is combined with specific symptom claims or disease references.

Structure/function claims with adequate substantiation. A brand with genuine clinical study data supporting a specific structure/function claim can make that claim with appropriate disclaimers. The substantiation bar is real but not impossible; it requires actual studies on the specific product or its key ingredient at the specific dose, not general literature reviews.

Third-party certification claims. Claims that a product is GMP-manufactured, ISO-tested, or certified by a recognized third-party quality organization are factual claims that support consumer confidence without crossing into health claim territory.

Implications for B2B Ingredient Suppliers

For B2B hemp ingredient suppliers, the FTC warning letter wave has a less obvious but real implication: the marketing materials, product descriptions, and technical documentation you provide to downstream customers can affect their marketing decisions — and potentially create your own secondary liability if those materials make health claims that enable downstream violations.

Ingredient suppliers should review their product documentation to confirm it does not make health claims that would be impermissible under the FTC standard. Technical data sheets, product brochures, and sales presentations that describe a hemp ingredient as "clinically shown to reduce anxiety" or "proven to support sleep" are making claims that downstream customers will reasonably incorporate into their own marketing — creating a documentation chain that connects the supplier's claims to the customer's FTC exposure.

The appropriate ingredient-level documentation describes the product's composition, testing methodology, manufacturing standards, and compliance status — not its health effects.

What to Do

• Audit your marketing materials for any disease treatment claims, unsubstantiated structure/function claims, or testimonial presentations that imply clinical efficacy.
• Review your ingredient supplier documentation to confirm it does not contain health claims that downstream customers might use in their own marketing.
• Consult with regulatory counsel before making any structure/function claims to confirm substantiation is adequate under FTC's standard.
• Update any testimonial sections on your website to remove statements that imply disease treatment or clinical efficacy.

Low Gravity Hemp provides compliant product documentation focused on composition, testing, and manufacturing standards — not health claims. Contact our team to review our documentation approach.